Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

Style" type="disc">
  • The Company is still in the development stage and has not generated any revenues. From inception through June 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $55.7 million and $41.6 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2010, the Company had cash and cash equivalents of approximately $4.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activity and to complete its plan of operations through December 31, 2010. At the Company's present level of activities, the Company's cash and cash equivalents are believed, at this time, to be sufficient to fund its operations only into the fourth quarter of 2010. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversel
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... Oct. 30, 2014 Today, DripDrop, the ... that it was awarded a two-year contract, effective ... company that serves the more than 100,000 members ... Association and Provista.  DripDrop also ... from member hospitals who attended the recent Novation ...
    (Date:10/30/2014)... , Oct. 29, 2014 The global ... of test type, technology, product, and geography. The ... highest growth rate in the newborn screening market ... growth is attributed to various nations opting for ... fundamental instrument used for expanded newborn screening. Furthermore, ...
    (Date:10/30/2014)... Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial results ... "During the quarter, we achieved a key objective ... a partner to accelerate the development and commercialization of PIXUVRI ... do not have a commercial presence while also retaining rights ... value of PIXUVRI for CTI and help us achieve our ...
    Breaking Medicine Technology:DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12
    ... 26 comScore, Inc. (Nasdaq: ... and ImpactRx, a pharmaceutical insights company, today released the ... Physician Behavioral Measurement™ solution, a unique digital measurement solution ... report found that 81 percent of physicians online visited ...
    ... Recognizing that venous interventions may potentially play an ... multiple sclerosis -- an incurable, disabling disease -- the ... indicating its support for high-quality clinical research to determine ... SIR,s position statement is endorsed by ...
    Cached Medicine Technology:4 out of 5 Physicians Online Visited Health Care Professional Sites in Q1 2010 24 out of 5 Physicians Online Visited Health Care Professional Sites in Q1 2010 34 out of 5 Physicians Online Visited Health Care Professional Sites in Q1 2010 4Society of Interventional Radiology Supports Research for New M.S. Treatments 2Society of Interventional Radiology Supports Research for New M.S. Treatments 3Society of Interventional Radiology Supports Research for New M.S. Treatments 4
    (Date:10/30/2014)... Nutrition Leaders, a popular online retailer of ... more, is currently hosting a sweepstakes on its official ... open to U.S. residents age 18 and over, and ... lucky winner will then be selected at random from ... to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba Vasquez ...
    (Date:10/30/2014)... (PRWEB) October 30, 2014 Graphics, coding, ... are synonymous with the craft of web design and ... website. Yet a simpler solution to create a website ... pictures, videos, contact information, customer reviews and Facebook posts ... "It is the next evolution of how a ...
    (Date:10/30/2014)... 2014 High efficacy and low ... the medical-grade skin care domain: Cosmederm, the specialty ... potent topical dermatological products, today announces the launch ... with patented COSMEDERM®-7 anti-irritant technology. , Formulated ... and 70%) and a low pH (pH 1.2 ...
    (Date:10/30/2014)... (PRWEB) October 30, 2014 PreDiabetes ... PreD Store shoppers with a supply of ... meals to reduce post-meal blood sugar spikes. Learning how ... is an important part of a diabetes prevention plan. ... will receive one complimentary tube of sugardown. The offer ...
    (Date:10/30/2014)... Haven, CT (PRWEB) October 30, 2014 ... categories are raising questions about the impact of traditional ... the marketing method most likely to influence a purchasing ... research poll of 525 consumers conducted by radio marketing ... four product categories, isolating the results of respondents who ...
    Breaking Medicine News(10 mins):Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
    ... be attributed to Jeff Smith, DVM, president, ... California Veterinary Medical Association:, SACRAMENTO, Calif., Oct. 15 ... a disappointment. The decision,of the Court of Appeals -- which ... the delivery of veterinary services in,California. The regulatory authority of ...
    ... the knowledge and treatment of schizophrenia, depression, ... Oct. 15 Five of the most prestigious ... of great,achievement by NARSAD, the world,s leading charity ... here this Friday at the,Waldorf-Astoria Hotel. Because ...
    ... for patients, researchers say , , MONDAY, Oct. 15 ... find nicotine patches or hot pepper-based chemicals on ... patches and the hot pepper-derivative capsaicin both provided ... presented at the American Society of Anesthesiologists, annual ...
    ... as a pivotal tumor suppressor for both human and mouse ... The research, published by Cell Press in the October 2007 ... of new drug therapies for lung cancer. , Lung cancer ... responsible for 1.3 million deaths each year. Non-small-cell lung cancers ...
    ... ALBUQUERQUE, N.M., Oct. 15 Two clinical,research scientists ... ( http://www.biomoda.com ) of Albuquerque, NM, to assist ... detection,testing and other cancer diagnostic technology. "Constance ... diagnostic products development and FDA regulations to,Biomoda. She ...
    ... 15 HMS Holdings Corp. (Nasdaq:,HMSY) today announced it will host a webcast ... the financial results for the,third quarter 2007, which ended September 30. Financial results ... Robert Holster, Chairman and CEO, WHEN: ... 10:00 AM ET, HOW: Presentation: ...
    Cached Medicine News:Health News:California Veterinary Medical Association Reacts to Supreme Court Decision 2Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 2Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 3Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3Health News:DMP1 deletion cooperates with oncogenic K-ras in lung cancer 2Health News:Two Scientists Join Team of Biomoda, Inc. 2Health News:HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation 2
    ... 14C have been approved. The three rings are ... in the size of the individual patients capsular ... to stabilize the capsule and have undergone extensive ... ophthalmologists. For implatations of the capsular tension ...
    Stainless steel cartilage scissors....
    Hibbs Retractor with sharp teeth. Used for deep soft tissue retraction....
    A general purpose instrument for use around the femur and acetabulum....
    Medicine Products: